Targeted therapy or immunotherapy in BRAF-mutated metastatic melanoma

Targeted therapies and immunotherapy are currently considered the mainstay first-line treatment for advanced BRAF-mutated melanoma. However, the impact of treatment (targeted therapy and immunotherapy) and the prognostic factors are still not clear. Medical records of 140 patients diagnosed with adv...

Descripción completa

Detalles Bibliográficos
Autores: Sun, Chen, España, Sofia|||0000-0002-7825-0734, Richarz, Nina, Solé-Blanch, Carme, Boada, Aram|||0000-0001-9809-5308, Martínez Cardús, Anna|||0000-0002-3937-8794, Chu, Alan, Liu, Zongwen, Manzano, Jose Luis
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:294068
Acceso en línea:https://ddd.uab.cat/record/294068
https://dx.doi.org/urn:doi:10.3389/fonc.2024.1322116
Access Level:acceso abierto
Palabra clave:Target therapy
Immunotherapy
Melanoma
BRAF mutation V600
Clinical experience
id ES_3aeafcc8371c3d8a8d367e7d1e39e714
oai_identifier_str oai:ddd.uab.cat:294068
network_acronym_str ES
network_name_str España
repository_id_str
spelling Targeted therapy or immunotherapy in BRAF-mutated metastatic melanomaa Spanish center's decade of experienceSun, ChenEspaña, Sofia|||0000-0002-7825-0734Richarz, NinaSolé-Blanch, CarmeBoada, Aram|||0000-0001-9809-5308Martínez Cardús, Anna|||0000-0002-3937-8794Chu, AlanLiu, ZongwenManzano, Jose LuisTarget therapyImmunotherapyMelanomaBRAF mutation V600Clinical experienceTargeted therapies and immunotherapy are currently considered the mainstay first-line treatment for advanced BRAF-mutated melanoma. However, the impact of treatment (targeted therapy and immunotherapy) and the prognostic factors are still not clear. Medical records of 140 patients diagnosed with advanced melanoma between 2011 and 2021 were retrospectively reviewed to extract demographic, BRAF status, treatment, performance status, and survival data. ORR, PFS, and OS were compared between patients diagnosed with advanced melanoma and treated with first-line IT or BRAF/MEKi. The prognostic factors were assessed using Cox regression models. In all patients and those treated with immunotherapy, we did not find any effect of BRAF status on ORR, PFS, or OS. In patients with BRAF-mutated melanoma, ORR was 43.8% vs. 70% (P=0.04), PFS was 19.2 vs. 11.5 months (p=0.22), and OS was 33.4 vs. 16.4 months for the immunotherapy and targeted therapy groups, respectively (P=0.04). ECOG, presence of brain metastases, and high LDH level from initiation of first-line treatment were all associated with differences in PFS and OS. Patients with advanced BRAF-mutated melanoma treated with first-line immunotherapy had a significantly longer PFS and OS than those treated with first-line BRAF/MEKi; however, first-line BRAF/MEKi treatment had a significantly higher ORR than first-line immunotherapy.Universitat Autònoma de Barcelona 22024-01-0120242024-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/294068https://dx.doi.org/urn:doi:10.3389/fonc.2024.1322116reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2940682026-06-06T12:50:31Z
dc.title.none.fl_str_mv Targeted therapy or immunotherapy in BRAF-mutated metastatic melanoma
a Spanish center's decade of experience
title Targeted therapy or immunotherapy in BRAF-mutated metastatic melanoma
spellingShingle Targeted therapy or immunotherapy in BRAF-mutated metastatic melanoma
Sun, Chen
Target therapy
Immunotherapy
Melanoma
BRAF mutation V600
Clinical experience
title_short Targeted therapy or immunotherapy in BRAF-mutated metastatic melanoma
title_full Targeted therapy or immunotherapy in BRAF-mutated metastatic melanoma
title_fullStr Targeted therapy or immunotherapy in BRAF-mutated metastatic melanoma
title_full_unstemmed Targeted therapy or immunotherapy in BRAF-mutated metastatic melanoma
title_sort Targeted therapy or immunotherapy in BRAF-mutated metastatic melanoma
dc.creator.none.fl_str_mv Sun, Chen
España, Sofia|||0000-0002-7825-0734
Richarz, Nina
Solé-Blanch, Carme
Boada, Aram|||0000-0001-9809-5308
Martínez Cardús, Anna|||0000-0002-3937-8794
Chu, Alan
Liu, Zongwen
Manzano, Jose Luis
author Sun, Chen
author_facet Sun, Chen
España, Sofia|||0000-0002-7825-0734
Richarz, Nina
Solé-Blanch, Carme
Boada, Aram|||0000-0001-9809-5308
Martínez Cardús, Anna|||0000-0002-3937-8794
Chu, Alan
Liu, Zongwen
Manzano, Jose Luis
author_role author
author2 España, Sofia|||0000-0002-7825-0734
Richarz, Nina
Solé-Blanch, Carme
Boada, Aram|||0000-0001-9809-5308
Martínez Cardús, Anna|||0000-0002-3937-8794
Chu, Alan
Liu, Zongwen
Manzano, Jose Luis
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Target therapy
Immunotherapy
Melanoma
BRAF mutation V600
Clinical experience
topic Target therapy
Immunotherapy
Melanoma
BRAF mutation V600
Clinical experience
description Targeted therapies and immunotherapy are currently considered the mainstay first-line treatment for advanced BRAF-mutated melanoma. However, the impact of treatment (targeted therapy and immunotherapy) and the prognostic factors are still not clear. Medical records of 140 patients diagnosed with advanced melanoma between 2011 and 2021 were retrospectively reviewed to extract demographic, BRAF status, treatment, performance status, and survival data. ORR, PFS, and OS were compared between patients diagnosed with advanced melanoma and treated with first-line IT or BRAF/MEKi. The prognostic factors were assessed using Cox regression models. In all patients and those treated with immunotherapy, we did not find any effect of BRAF status on ORR, PFS, or OS. In patients with BRAF-mutated melanoma, ORR was 43.8% vs. 70% (P=0.04), PFS was 19.2 vs. 11.5 months (p=0.22), and OS was 33.4 vs. 16.4 months for the immunotherapy and targeted therapy groups, respectively (P=0.04). ECOG, presence of brain metastases, and high LDH level from initiation of first-line treatment were all associated with differences in PFS and OS. Patients with advanced BRAF-mutated melanoma treated with first-line immunotherapy had a significantly longer PFS and OS than those treated with first-line BRAF/MEKi; however, first-line BRAF/MEKi treatment had a significantly higher ORR than first-line immunotherapy.
publishDate 2024
dc.date.none.fl_str_mv 2
2024-01-01
2024
2024-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/294068
https://dx.doi.org/urn:doi:10.3389/fonc.2024.1322116
url https://ddd.uab.cat/record/294068
https://dx.doi.org/urn:doi:10.3389/fonc.2024.1322116
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406272860717056
score 15,811543

Similares en LA Referencia